Cargando…
Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
The aim of this study was to evaluate the efficacy of a treat-and-extend (T&E) regimen of ranibizumab as the first-choice treatment in macular oedema (MO) secondary to branch retinal vein occlusion (BRVO). We conducted a retrospective study of 20 patients who developed MO due to BRVO treated wit...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778817/ https://www.ncbi.nlm.nih.gov/pubmed/35056116 http://dx.doi.org/10.3390/ph15010059 |
_version_ | 1784637416163770368 |
---|---|
author | Rodríguez-Fernández, Carmen Antía Campo-Gesto, Ana López-López, Aida Gayoso-Rey, Mónica |
author_facet | Rodríguez-Fernández, Carmen Antía Campo-Gesto, Ana López-López, Aida Gayoso-Rey, Mónica |
author_sort | Rodríguez-Fernández, Carmen Antía |
collection | PubMed |
description | The aim of this study was to evaluate the efficacy of a treat-and-extend (T&E) regimen of ranibizumab as the first-choice treatment in macular oedema (MO) secondary to branch retinal vein occlusion (BRVO). We conducted a retrospective study of 20 patients who developed MO due to BRVO treated with intravitreal ranibizumab in a T&E regimen between 2016 and 2017 with a minimum follow-up of two years. Patients were classified as complete responders if treated with ranibizumab alone or incomplete responders if salvage treatment with other medications or laser was needed. Data on best corrected visual acuity (BCVA) and central macular thickness (CMT) every 6 months were recorded. The mean BCVA (logMAR) improved from 0.60 ± 0.36 to 0.29 ± 0.44 and the CMT decreased from 559.85 ± 198.61 to 305.85 ± 11.78 μm. We found statistically significant differences between complete and incomplete responders on the average number of injections during the second year (2.46 ± 2.18 compared to 5.43 ± 1.27; p = 0.007) and change of the BCVA and CMT between both groups (p < 0.001) at 6, 12, 18 and 24 months. T&E seems to be effective in MO secondary to BRVO, improving visual function and decreasing CMT, with less need for injections. |
format | Online Article Text |
id | pubmed-8778817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87788172022-01-22 Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion Rodríguez-Fernández, Carmen Antía Campo-Gesto, Ana López-López, Aida Gayoso-Rey, Mónica Pharmaceuticals (Basel) Article The aim of this study was to evaluate the efficacy of a treat-and-extend (T&E) regimen of ranibizumab as the first-choice treatment in macular oedema (MO) secondary to branch retinal vein occlusion (BRVO). We conducted a retrospective study of 20 patients who developed MO due to BRVO treated with intravitreal ranibizumab in a T&E regimen between 2016 and 2017 with a minimum follow-up of two years. Patients were classified as complete responders if treated with ranibizumab alone or incomplete responders if salvage treatment with other medications or laser was needed. Data on best corrected visual acuity (BCVA) and central macular thickness (CMT) every 6 months were recorded. The mean BCVA (logMAR) improved from 0.60 ± 0.36 to 0.29 ± 0.44 and the CMT decreased from 559.85 ± 198.61 to 305.85 ± 11.78 μm. We found statistically significant differences between complete and incomplete responders on the average number of injections during the second year (2.46 ± 2.18 compared to 5.43 ± 1.27; p = 0.007) and change of the BCVA and CMT between both groups (p < 0.001) at 6, 12, 18 and 24 months. T&E seems to be effective in MO secondary to BRVO, improving visual function and decreasing CMT, with less need for injections. MDPI 2022-01-03 /pmc/articles/PMC8778817/ /pubmed/35056116 http://dx.doi.org/10.3390/ph15010059 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rodríguez-Fernández, Carmen Antía Campo-Gesto, Ana López-López, Aida Gayoso-Rey, Mónica Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion |
title | Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion |
title_full | Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion |
title_fullStr | Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion |
title_full_unstemmed | Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion |
title_short | Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion |
title_sort | real-world evidence for treat-and-extend regimen of ranibizumab therapy for macular oedema secondary to branch retinal vein occlusion |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778817/ https://www.ncbi.nlm.nih.gov/pubmed/35056116 http://dx.doi.org/10.3390/ph15010059 |
work_keys_str_mv | AT rodriguezfernandezcarmenantia realworldevidencefortreatandextendregimenofranibizumabtherapyformacularoedemasecondarytobranchretinalveinocclusion AT campogestoana realworldevidencefortreatandextendregimenofranibizumabtherapyformacularoedemasecondarytobranchretinalveinocclusion AT lopezlopezaida realworldevidencefortreatandextendregimenofranibizumabtherapyformacularoedemasecondarytobranchretinalveinocclusion AT gayosoreymonica realworldevidencefortreatandextendregimenofranibizumabtherapyformacularoedemasecondarytobranchretinalveinocclusion |